Enanta Pharmaceuticals (ENTA) Competitors

$12.20 -0.32 (-2.56%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.20 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

ENTA vs. ANIP, LBRX, XERS, PAHC, and INVA

Should you buy Enanta Pharmaceuticals stock or one of its competitors? Enanta Pharmaceuticals's main competitors and comparable companies include ANI Pharmaceuticals (ANIP), LB Pharmaceuticals (LBRX), Xeris Biopharma (XERS), Phibro Animal Health (PAHC), and Innoviva (INVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Enanta Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$4.64	16.41
Enanta Pharmaceuticals	$65.26M	5.44	-$81.89M	-$2.41	N/A

ANI Pharmaceuticals has a net margin of 11.07% compared to Enanta Pharmaceuticals' net margin of -96.89%. ANI Pharmaceuticals' return on equity of 27.37% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ANI Pharmaceuticals presently has a consensus target price of $103.00, suggesting a potential upside of 35.28%. Enanta Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 72.13%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, ANI Pharmaceuticals had 15 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 15 mentions for ANI Pharmaceuticals and 0 mentions for Enanta Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.76 beat Enanta Pharmaceuticals' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Enanta Pharmaceuticals	Neutral

Summary

ANI Pharmaceuticals beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LB Pharmaceuticals has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. LB Pharmaceuticals' return on equity of -25.92% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

LB Pharmaceuticals has higher earnings, but lower revenue than Enanta Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Enanta Pharmaceuticals	$65.26M	5.44	-$81.89M	-$2.41	N/A

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for LB Pharmaceuticals and 0 mentions for Enanta Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.42 beat Enanta Pharmaceuticals' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
LB Pharmaceuticals	Neutral
Enanta Pharmaceuticals	Neutral

LB Pharmaceuticals currently has a consensus price target of $49.63, suggesting a potential upside of 16.85%. Enanta Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 72.13%. Given Enanta Pharmaceuticals' higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

LB Pharmaceuticals beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Xeris Biopharma has a net margin of -5.12% compared to Enanta Pharmaceuticals' net margin of -96.89%. Xeris Biopharma's return on equity of 338.21% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Xeris Biopharma	-5.12%	338.21%	3.50%

In the previous week, Xeris Biopharma had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Xeris Biopharma and 0 mentions for Enanta Pharmaceuticals. Xeris Biopharma's average media sentiment score of 1.02 beat Enanta Pharmaceuticals' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Xeris Biopharma	Positive

Enanta Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Enanta Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.26M	5.44	-$81.89M	-$2.41	N/A
Xeris Biopharma	$291.85M	5.12	$550K	-$0.11	N/A

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals presently has a consensus price target of $21.00, indicating a potential upside of 72.13%. Xeris Biopharma has a consensus price target of $12.80, indicating a potential upside of 56.10%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Enanta Pharmaceuticals and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Phibro Animal Health had 14 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 14 mentions for Phibro Animal Health and 0 mentions for Enanta Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.61 beat Enanta Pharmaceuticals' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Phibro Animal Health	Positive

Enanta Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Enanta Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 72.13%. Phibro Animal Health has a consensus target price of $47.67, indicating a potential upside of 37.92%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enanta Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Phibro Animal Health has a net margin of 6.57% compared to Enanta Pharmaceuticals' net margin of -96.89%. Phibro Animal Health's return on equity of 37.86% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Phibro Animal Health	6.57%	37.86%	9.18%

Phibro Animal Health has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.26M	5.44	-$81.89M	-$2.41	N/A
Phibro Animal Health	$1.52B	0.92	$99.72M	$2.44	14.16

Summary

Phibro Animal Health beats Enanta Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Innoviva?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Enanta Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Innoviva has a net margin of 81.19% compared to Enanta Pharmaceuticals' net margin of -96.89%. Innoviva's return on equity of 28.03% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Innoviva	81.19%	28.03%	20.19%

Innoviva has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.26M	5.44	-$81.89M	-$2.41	N/A
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.16

Enanta Pharmaceuticals currently has a consensus target price of $21.00, suggesting a potential upside of 72.13%. Innoviva has a consensus target price of $34.75, suggesting a potential upside of 64.38%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Innoviva	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Innoviva had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for Innoviva and 0 mentions for Enanta Pharmaceuticals. Innoviva's average media sentiment score of 1.57 beat Enanta Pharmaceuticals' score of 0.00 indicating that Innoviva is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Innoviva	Very Positive

Summary

Innoviva beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$364.65M	$12.45B	$7.24B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-5.06	797.25	275.79	25.40
Price / Sales	5.44	950.97	695.58	114.44
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	4.03	10.53	10.46	6.33
Net Income	-$81.89M	$2.82B	$3.49B	$358.33M
7 Day Performance	-5.86%	1.69%	0.59%	1.12%
1 Month Performance	-9.70%	0.83%	-2.01%	-2.67%
1 Year Performance	59.69%	3.90%	18.09%	6.01%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.6914 of 5 stars	$12.20 -2.6%	$21.00 +72.1%	+55.6%	$355.32M	$65.32M	N/A	120
ANIP ANI Pharmaceuticals	4.1778 of 5 stars	$70.23 -1.4%	$105.83 +50.7%	-21.9%	$1.64B	$883.37M	15.14	600	Insider Trade
LBRX LB Pharmaceuticals	1.8782 of 5 stars	$49.39 +0.1%	$49.63 +0.5%	N/A	$1.59B	N/A	N/A	16
XERS Xeris Biopharma	4.1447 of 5 stars	$8.48 -0.6%	$12.00 +41.5%	-1.2%	$1.56B	$291.85M	N/A	290	Positive News Analyst Upgrade
PAHC Phibro Animal Health	4.1635 of 5 stars	$37.31 -2.5%	$47.67 +27.8%	-14.8%	$1.55B	$1.52B	15.29	2,605	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. ANIP, LBRX, XERS, PAHC, and INVA

How does Enanta Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Enanta Pharmaceuticals compare to LB Pharmaceuticals?

Summary

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Enanta Pharmaceuticals compare to Innoviva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. ANIP, LBRX, XERS, PAHC, and INVA

How does Enanta Pharmaceuticals compare to ANI Pharmaceuticals?

Which has more risk and volatility, ANIP or ENTA?

Which has stronger earnings and valuation, ANIP or ENTA?

Is ANIP or ENTA more profitable?

Do institutionals and insiders hold more shares of ANIP or ENTA?

Do analysts rate ANIP or ENTA?

Does the media refer more to ANIP or ENTA?

Summary

How does Enanta Pharmaceuticals compare to LB Pharmaceuticals?

Do institutionals & insiders believe in LBRX or ENTA?

Is LBRX or ENTA more profitable?

Which has preferable earnings & valuation, LBRX or ENTA?

Does the media prefer LBRX or ENTA?

Do analysts prefer LBRX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Is ENTA or XERS more profitable?

Does the media refer more to ENTA or XERS?

Which has more volatility and risk, ENTA or XERS?

Which has preferable valuation and earnings, ENTA or XERS?

Do institutionals and insiders have more ownership in ENTA or XERS?

Do analysts rate ENTA or XERS?

Summary

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Do institutionals & insiders have more ownership in ENTA or PAHC?

Does the media refer more to ENTA or PAHC?

Which has more risk and volatility, ENTA or PAHC?

Do analysts rate ENTA or PAHC?

Is ENTA or PAHC more profitable?

Which has stronger earnings and valuation, ENTA or PAHC?

Summary

How does Enanta Pharmaceuticals compare to Innoviva?

Do insiders & institutionals hold more shares of ENTA or INVA?

Which has more volatility and risk, ENTA or INVA?

Is ENTA or INVA more profitable?

Which has better valuation & earnings, ENTA or INVA?

Do analysts rate ENTA or INVA?

Does the media refer more to ENTA or INVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools